Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 8/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907514 | 0.92 | HTR5A (0.48) | HTR5AMAP2K4CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907515 | 0.91 | HTR5A (0.67) | HTR5AMAP2K4CSNK2A1MAPTMEN1 | |
| SCHEMBL9907754 | 0.90 | HTR5A (0.47) | HTR5AMAP2K4CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907730 | 0.90 | MAP2K4 (0.46) | HTR5ACNR1MAP2K4ALPLCSNK2A2 | |
| SCHEMBL9909280 | 0.89 | SCN9A (0.52) | HTR5AMAP2K4CSNK2A2CSNK2BMEN1 | |
| SCHEMBL9908001 | 0.89 | HTR5A (0.53) | HTR5ACSNK2A2CSNK2BCSNK2A1SCN9A | |
| SCHEMBL9907637 | 0.87 | HTR5A (0.66) | HTR5AMAPT | |
| SCHEMBL9907714 | 0.86 | HTR5A (0.55) | HTR5AMAP2K4CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907696 | 0.86 | HTR5A (0.59) | HTR5ACNR1MAP2K4MAPT | |
| SCHEMBL9907648 | 0.85 | HTR5A (0.50) | HTR5ACSNK2A2CSNK2BCSNK2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885CNR1 455/4885MAP2K4 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.